Simponi (Rheumatoid Arthritis) Forecast And Market Analysis - New Market Study Published

New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

by Bill Thompson

(WireNews+Co) - Boston, MA - 20 February 2013

GlobalData has released its new PharmaPoint Drug Evaluation report, Simponi (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market. Johnson & Johnson's Simponi (golimumab) is a subcutaneous fully human IgG1 mAb specific for TNF-alpha. It inhibits TNF-alpha activity, thereby modulating immune activity in RA patients and thus blocking inflammatory activity of TNF-alpha. Simponi is prescribed to patients with moderate to severe active RA who have failed another anti-TNF agent or had unsatisfactory response with MTX. It is also prescribed for other immunological indications including ankylosing spondylitis and psoriatic arthritis.

View Full Report Details (http://www.fastmr.com/prod/529854_simponi_rheumatoid_arthritis_forecast_and_market.aspx?afid=201) (http://www.fastmr.com/prod/529854_simponi_rheumatoid_arthritis_forecast_and_market.aspx?afid=201)

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Simponi (golimumab) including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Simponi (golimumab) for the top eight countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Simponi (golimumab) performance
- Obtain sales forecast for Simponi (golimumab) from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia).

Fast Market Research (http://www.fastmr.com?afid=201) is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget.  For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.